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Abstract
Exciting new technologies for assessing markers in human specimens are now available to evaluate unprecedented
types and numbers of variations in DNA, RNA, proteins, or biological structures such as chromosomes. These
markers, whether viewed individually, or collectively as a ‘signature’, have the potential to be useful for disease risk
assessment, screening, early detection, prognosis, therapy selection, and monitoring for therapy effectiveness or
disease recurrence. Successful translation from basic research findings to clinically useful test requires basic,
translational, and regulatory sciences and a collaborative effort among individuals with varied types of expertise
including laboratory scientists, technology developers, clinicians, statisticians, and bioinformaticians. The focus of
this commentary is the many statistical challenges in translational marker research, specifically in the development
and validation of marker-based tests that have clinical utility for therapeutic decision-making.
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Introduction
It is increasingly recognized that many therapies will
benefit only a subgroup of patients. Indeed, many new
therapies are being engineered to target specific biologi-
cal features of disease which, in turn, identify particular
patient subgroups most likely to benefit from the ther-
apy. In oncology, for example, the genetic makeup of a
tumor might determine the biological pathways upon
which it is dependent for survival and growth, and tar-
geting components of that pathway with a new therapy
might be the key to eradicating the tumor or arresting
its growth [1]. Tumors not dependent on that pathway
might be unaffected by the new therapy. Variations in
germline DNA resulting in deficiency of drug metaboliz-
ing enzymes might dramatically influence a patient’s risk
of serious toxicities from certain drugs [2]. Therefore,
clinical tests based on biological markers can be useful
for making therapeutic decisions for patients newly diag-
nosed with a disease or for informing clinical manage-
ment decisions throughout course of treatment.
The main types of marker-based tests for guiding
therapy decisions at time of initial diagnosis are predic-
tive tests, and to a lesser extent, prognostic tests [3]. In
oncology terms, predictive markers are those associated
with response (benefit) or lack of response to a particu-
lar therapy relative to other available therapy. In other
medical specialties, terms such as treatment effect modi-
fier, treatment-guiding marker, or treatment-selection
marker are often used.
For some diseases there can be wide variation in the
natural course of the disease process. Some patients
may have very indolent disease with symptoms so mild
that no, or minimal, therapy is recommended, whereas
o t h e rp a t i e n t sm i g h th a v eav e r ya g g r e s s i v ef o r mo ft h e
disease requiring intensive treatment. In these cases,
prognostic markers may be useful in making these dis-
tinctions. These predict natural history of disease in the
absence of further therapy. Sometimes this definition of
prognostic marker is extended to natural history in the
context of standard therapy that all patients are likely to
receive. Marker-based tests that provide clinically
important prognostic or predictive information are
rapidly becoming integral to development and optimal
utilization of therapeutics. Correspondence: McShaneL@CTEP.NCI.NIH.gov
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methods has long been recognized in clinical trials for
new therapeutics, but the same rigor often does not
exist in the development and evaluation of marker-
based tests. In oncology, there has been much discus-
sion of the disappointing rate of progress in moving
marker-based tests into clinical practice. The description
provided in the American Society of Clinical Oncology
2007 Update of Recommendations for the Use of
Tumor Markers in Breast Cancer typifies the situation:
‘... primary literature is characterized by studies that
included small patient numbers, that are retrospective,
and that commonly perform multiple analyses until one
reveals a statistically significant result’ [4]. This charac-
terization is further supported by an oncology literature
review conducted by Kyzas et al. [5] which found that
‘almost all articles on cancer prognostic markers report
statistically significant results’.
Few tumor prognostic markers ever make it into rou-
tine clinical practice to have an impact on patient care
or outcomes. Although these examples come from
oncology, the issues are widely applicable to marker
research in other medical subspecialties. This commen-
tary will explain how deficiencies in study design and
statistical analysis methods have been large contributors
to the modest rate of progress in translational marker
research.
Discussion
Marker studies should ideally be designed and con-
ducted with a specific clinical question in mind just like
therapeutic trials, but unfortunately, rigorously con-
ducted marker studies seem to be the exception rather
than the rule [6]. Many marker studies are conducted
with a lack of attention to design and in the absence of
a clinically meaningful marker question, that is, for what
clinical use the marker is being considered or proposed
[7]. Frequently marker studies are conducted retrospec-
tively on ‘convenience’ specimen sets, which are speci-
men sets assembled based on availability, and may
represent patients with highly diverse pathologic and
clinical characteristics. The specimens may have been
collected under unknown conditions, and the quality
and completeness of associated clinical and pathological
data may be unreliable. All of this heterogeneity makes
it difficult to identify a coherent clinical setting in which
the marker might be useful, even if the study is able to
identify statistically significant associations between the
marker and patient characteristics or outcomes.
Ideal execution of retrospective prognostic marker
studies
Specimens collected in the context of clinical trials, pro-
spective cohort studies, or well-monitored prospective
registries and which are stored for future use are the
optimal source of specimens for retrospective prognostic
studies [8]. Potential prognostic markers can be evalu-
ated appropriately using specimens collected from
patients enrolled on a placebo arm of a trial or an arm
representing standard of care for the disease setting
under study. Prognostic studies can also be conducted
using specimens collected as part of prospective disease
registries or from subjects in epidemiological study
cohorts who were observed to develop disease if the
clinical follow-up of the subjects who developed disease
is sufficiently standardized and complete. Specimens col-
lected from these sources are most likely to have been
collected in a standardized fashion, the associated patho-
logic and clinical data tend to be most reliable, and
therefore, the study is more likely to produce interpreta-
ble and convincing findings than studies conducted on
convenience sets of specimens.
Ideal execution of retrospective predictive marker studies
Predictive marker studies are most reliable when con-
ducted using specimens that had been collected as part
of a prospective clinical trial that randomized patients
between a standard of care treatment and a new therapy
for which the marker is being assessed for its predictive
utility. Such specimen collections can be used to provide
a high level of evidence for a marker’sp r e d i c t i v eo r
prognostic clinical utility under appropriate conditions,
including careful pre-specification of the statistical ana-
lysis plan for evaluation of the marker [8].
A risky practice in the evaluation of predictive mar-
kers is to look for an association of a marker with clini-
cal outcome by studying only patients who receive the
new therapy. The problem with this approach is that
prognostic effects can be confused with predictive
effects. Suppose, for example, that the marker under
study has a substantial prognostic effect so that patients
with high levels of the marker will have better clinical
outcome than patients with low levels of the marker
regardless of what treatment the patient receives. Look-
ing only at the patients treated with the new therapy
might lead one to conclude erroneously that the
improved outcome for patients with high levels of the
marker was due to a preferential benefit of the new
therapy for that marker-defined subgroup when, in fact,
it is possible that the new therapy benefits no patients.
Results of these types of studies can be misleading in
the opposite direction as well. This can occur if the
marker predicts for poor outcome under standard ther-
apy, but patients with this marker benefit from the new
therapy. The marker might exhibit no association with
clinical outcome in the setting of new therapy, but only
because the outcome for patients who were positive for
the marker had been improved by the new therapy to
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positive for the marker. These examples underscore the
need for examination of an appropriate control group
(placebo or standard of care) when evaluating a poten-
tial predictive marker. A randomized trial provides an
ideal setting to ensure that no other confounding factors
influenced which patients received the standard therapy
versus the new therapy.
Extensive exploratory data analyses may result in
spurious findings
Often extensive data analyses are performed in prognos-
tic and predictive studies in a quest for associations
between markers and clinical outcomes that demon-
strate statistically significant P values. With the possibi-
lity to test association of multiple markers with multiple
clinical endpoints in several patient subgroups, the
chance of generating spuriously significant results in ret-
rospective prognostic and predictive marker studies can
be substantial [9].
Consider testing the association between a marker and
a clinical outcome in each of four disjoint patient sub-
groups. If each statistical test is performed at the usual
significance level of 0.05, the probability that a statisti-
cally significant result will be obtained in at least one of
the four subgroups is 19%. Now consider multiple types
of clinical outcomes and multiple markers and multiple
cut-points applied to dichotomize continuous markers,
and the likelihood of such a study producing at least
one statistically significant result by chance can become
very large. A similar problem occurs when treatment
differences are tested in a clinical trial comparing two
or more treatments arms in a multitude of subsets
defined by markers or other patient characteristics. If
treatment differences are found in some subsets and not
others, investigators are tempted to claim that they have
identified predictive subgroups. Most often such findings
are spurious due to the multiple testing and are not
confirmed in subsequent studies. Statisticians sometimes
explain this phenomenon as ‘if you torture the data long
enough, they will confess to anything’. If these statisti-
cally significant findings are then retrofitted to a clinical
question and published with no indication of the
exploratory context in which the results were obtained,
the result may represent a serious distortion of the sig-
nificance (both statistical and clinical) of the findings.
Together with the long recognized problem of publica-
tion bias favoring studies that report positive findings,
t h er e s u l tm a yb eab o d yo fl i t e r a t u r et h a ti sh e a v i l y
influenced by false-positive findings.
Sample sizes for adequate statistical power
Evaluation of predictive andp r o g n o s t i cm a r k e r su s i n g
specimens collected within treatment trials is not a
panacea, however. When designing clinical trials, sample
size is generally determined to permit sufficient statisti-
cal power to detect a treatment effect of a pre-specified
size. Often marker questions are either not specified
during the planning stage for a therapeutic trial, or if
they are, they are usually relegated to secondary aims
that the study might not be sized to address with high
statistical power. Add to that an inability to collect spe-
cimens from some patients in the trial, and statistical
power can be diminished further. Major determinants of
statistical power for analyses examining prognostic and
predictive markers and their association with time-to-
event endpoints (for example, time to disease recurrence
or progression, or time to death) include the testing sig-
nificance level (alpha or type I error), the expected num-
ber of events, the distribution of the marker (for
example, positivity rate for a binary marker), the treat-
ment randomization ratio, and the magnitude of effect.
Understanding the proper quantification of prognostic
and predictive effects is important for determination of
clinical utility and proper study design to evaluate those
effects. For survival analyses, the effect of a binary prog-
nostic marker is usually expressed as a hazard ratio. The
relevant effect for a binary predictive marker is a treat-
ment-by-marker interaction. Presence of a treatment-by-
marker interaction means that the treatment effect, that
is, the difference in clinical outcome between a new
treatment and a standard treatment, differs depending
on the status of the patient’s marker. An interaction
effect is often expressed in statistical terms as a ratio of
the treatment hazard ratios, with one treatment hazard
ratio being calculated in the marker ‘positive’ subgroup
and the other treatment hazard ratio being calculated in
the marker ‘negative’ subgroup. A treatment-by-marker
interaction is most clinically relevant when it is a quali-
tative interaction. Qualitative means that the direction
of treatment benefit is reversed in one marker subgroup
compared to the other. For example, the new treatment
might confer a substantial survival advantage to patients
who are positive for the marker, but it may be the same
or worse than standard treatment in the marker nega-
tive subgroup. Quantitative interactions occur when the
treatment benefit is in the same direction but of differ-
ent magnitude in the two patient subgroups. Unless the
differential magnitude leads to a different treatment
decision, a quantitative interaction may not translate to
clinical utility of a test based on the marker.
The statistical power of a prognostic or predictive mar-
ker study depends on the distribution of the marker
values in the patient population as well as the size of the
effect that one aims to detect. When comparing survival
between two groups of patients, for example, patients
who receive two different treatments or patients whose
tumors do versus do not express a particular marker,
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Therefore, if a clinical trial has been designed with one-
to-one randomization to detect a specified hazard ratio
between treatment groups, a test for the effect of a binary
prognostic marker on clinical outcome of the same mag-
nitude as the treatment effect will have lower power than
the treatment comparison when the binary marker has
prevalence substantially different than 50%.
To test a marker-by-treatment interaction, the situa-
tion is even more challenging. To adequately power a
clinical trial to test a treatment by marker interaction
can easily require two to four times the sample size
required to detect a treatment effect unless there is a
fairly dramatic treatment effect nearly exclusive to the
biomarker-predicted benefiting subgroup. Importantly,
the biomarker-defined subgroup should not be defined
post hoc by exploratory analyses and then tested as
though it had been pre-specified unless proper care has
been taken to statistically adjust for this form of multi-
ple testing to avoid false-positive findings. An added
problem is the inaccuracy of some marker assays. If
assay inaccuracies cause misclassification of patients
with regard to marker status, this error will cause
further reduction in the statistical power for detecting
predictive marker effects. Taken together, the considera-
tions just discussed explain why it can be so difficult to
establish utility of prognostic and predictive marker
tests in a statistically rigorous way when the marker-
related questions are retrofitted to therapeutics trials.
If there exist no suitable treatment trials with ade-
quate specimen collection to adequately answer an
important predictive or prognostic marker question, sev-
eral options remain. These are to prospectively design a
trial to specifically answer the marker question, or to try
to combine specimens or marker data across several
completed trials. Many options have been proposed for
designing trials to validate marker-based tests [10], but
such trials can be costly and currently are conducted
less frequently than trials designed purely to answer a
treatment question. Alternatively, combining over differ-
ent marker studies might be possible, but care must be
taken to select studies to represent the full spectrum of
relevant studies, regardless of publication status or pre-
sence of statistically significant findings. Not only must
patient characteristics and treatments be comparable in
order for the studies to be combined sensibly, but the
marker assays used in the different studies need to be
comparable. All of these options require adequate
resources, clear and unbiased reporting of studies, shar-
ing of data, and potentially sharing of specimens.
Conclusions
As marker-based clinical tests play an increasingly more
prominent role in therapeutic decision-making,
correspondingly greater attention needs to be paid to
scientific rigor and clinical relevance earlier in the devel-
opment and in the validation of such tests. This will
require formation of collaborative teams including parti-
cipation by laboratory scientists, technology developers,
clinicians, statisticians, and bioinformaticians. Earlier
emphasis should be placed on quality standards for speci-
men and data collection and pre-specified statistical ana-
lysis plans so that markers do not languish in never-
ending cycles of confusing exploratory or poorly designed
or analyzed studies. A comprehensive biomarker study
registry has been proposed [11] and is currently under
development. It is hoped that such a registry will make it
easier to assess the body of evidence that already exists,
and to identify studies that might be relevant for sys-
tematic reviews and meta-analyses. Studies need to be
reported more thoroughly and transparently so that
s t u d yq u a l i t ya n dr e l e v a n c ec a nb ej u d g e dm o r ee a s i l y .
Reporting guidelines for a variety of different types of
biomedical research studies are now available http://
www.equator-network.org/research-projects/. Specifically
for tumor marker studies, the REMARK guidelines
[12,13] provide useful guidance for reporting. The BRISQ
guidelines [14] provide helpful guidance for reporting
information about specimens used in biomedical studies.
T h e s ee f f o r t sw i l lp r o v i d eam o r er e p r e s e n t a t i v eb o d yo f
evidence upon which to base decisions about the clinical
utility of marker-based tests.
Authors’ information
LM is a senior Mathematical Statistician in the Biometric Research Branch in
the Division of Cancer Treatment and Diagnosis at the US National Cancer
Institute where she works closely with the Cancer Diagnosis Program and
Cancer Therapy Evaluation Program. Her statistical and collaborative interests
and publications cover diverse topics including prognostic and predictive
markers, genomic profiling, statistical design of prognostic and predictive
marker studies, methods for the analysis of high-dimensional genomic data,
multiple comparisons methods, surrogate endpoints, measurement error
adjustment methods, and laboratory quality control and assay reproducibility
assessment. She co-led the group that authored the REMARK guidelines for
reporting tumor marker studies and is a co-author of the book Design and
Analysis of DNA Microarray Investigations. Currently LM is a member of the
Scientific Advisory Board of Science Translational Medicine.
Competing interests
The author declares that they have no competing interests.
Received: 8 February 2012 Accepted: 29 May 2012
Published: 29 May 2012
References
1. Schilsky RS: Personalizing cancer care: American Society of Clinical
Oncology presidential address 2009. J Clin Oncol 2009, 27:3725-3730.
2. Gardiner SJ, Begg EJ: Pharmacogenetics, drug-metabolizing enzymes, and
clinical practice. Pharmacol Rev 2006, 58:521-590.
3. Clark GM, McShane LM: Biostatistical considerations in development of
biomarker-based tests to guide treatment decisions. Statistics in
Biopharmaceutical Research 2011, 3:549-560.
4. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR,
Hayes DF, Bast RC Jr: American Society of Clinical Oncology 2007 update
McShane BMC Medicine 2012, 10:52
http://www.biomedcentral.com/1741-7015/10/52
Page 4 of 5of recommendations for the use of tumor markers in breast cancer. J
Clin Oncol 2007, 25:5287-5312.
5. Kyzas PA, Denaxa-Kyza D, Ioannidis JPA: Almost all articles on cancer
prognostic markers report statistically significant results. Eur J Cancer
2007, 43:2559-2579.
6. Simon R, Altman DG: Statistical aspects of prognostic factor studies in
oncology. Br J Cancer 1994, 69:979-985.
7. Simon R: Development and validation of therapeutically relevant multi-
gene biomarker classifiers. J Natl Cancer Inst 2005, 97:866-867.
8. Simon RM, Paik S, Hayes DF: Use of archived specimens in evaluation of
prognostic and predictive biomarkers. J Natl Cancer Inst 2009,
101:1446-1452.
9. Ioannidis JPA: Limits to forecasting in personalized medicine: An
overview. Int J Forecast 2009, 25:773-783.
10. Freidlin B, McShane LM, Korn EL: Randomized clinical trials with
biomarkers: design issues. J Natl Cancer Inst 2010, 102:152-160.
11. Andre F, McShane LM, Michiels S, Ransohoff DF, Altman DG, Reis-Filho JS,
Hayes DF, Pusztai L: Biomarker studies: a call for a comprehensive
biomarker study registry. Nat Rev Clin Oncol 2011, 8:171-176.
12. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM,
Statistics Subcommittee of the NCIC-EORTC Working Group on Cancer
Diagnostics: REporting recommendations for tumor MARKer prognostic
studies (REMARK). J Natl Cancer Inst 2005, 97:1180-1184.
13. Altman DG, McShane LM, Sauerbrei W, Taube SE: Reporting
recommendations for tumor marker prognostic studies (REMARK):
explanation and elaboration. BMC Medicine 2012, 10:51.
14. Moore HM, Kelly AB, Jewell SD, McShane LM, Clark DP, Greenspan R,
Hayes DF, Hainaut P, Kim P, Mansfield EA, Potapova O, Riegman P,
Rubinstein Y, Seijo E, Somiari S, Watson P, Weier H-U, Zhu C, Vaught J:
Biospecimen Reporting for Improved Study Quality (BRISQ). Cancer
Cytopathol 2011, 119:92-101.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1741-7015/10/52/prepub
doi:10.1186/1741-7015-10-52
Cite this article as: McShane: Statistical challenges in the development
and evaluation of marker-based clinical tests. BMC Medicine 2012 10:52.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
McShane BMC Medicine 2012, 10:52
http://www.biomedcentral.com/1741-7015/10/52
Page 5 of 5